Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies.
Gambacorti-Passerini
C
C
Gasser
M
M
Ahmed
S
S
Assouline
S
S
Scapozza
L
L
D003198:Computer Simulation; D000069439:Dasatinib; D008958:Models, Molecular; D011485:Protein Binding / Q000187:drug effects; D011487:Protein Conformation; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D017434:Protein Structure, Tertiary; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000737:chemistry*; D016315:Proto-Oncogene Proteins c-abl / Q000037:antagonists & inhibitors / Q000737:chemistry*; D011743:Pyrimidines / Q000737:chemistry* / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013844:Thiazoles / Q000737:chemistry* / Q000494:pharmacology
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D011505:Protein-Tyrosine Kinases; D016315:Proto-Oncogene Proteins c-abl; D000069439:Dasatinib